Amylyx Pharmaceuticals will withdraw its ALS drug – its only product in the market – from the U.S. and Canada after the treatment failed in a key late-stage trial.
Amylyx Pharmaceuticals will withdraw its ALS drug – its only product in the market – from the U.S. and Canada after the treatment failed in a key late-stage trial.